Stamos Capital Partners, L.P. Bio N Tech Se Transaction History
Stamos Capital Partners, L.P.
- $412 Million
- Q3 2024
Shares
1 transactions
Others Institutions Holding BNTX
# of Institutions
356Shares Held
38.3MCall Options Held
2.45MPut Options Held
2.29M-
Baillie Gifford & CO8.31MShares$940 Million0.75% of portfolio
-
Primecap Management CO Pasadena, CA4.52MShares$511 Million0.4% of portfolio
-
Flossbach Von Storch Ag Cologne, 2M4.36MShares$493 Million2.05% of portfolio
-
Black Rock Inc. New York, NY1.9MShares$214 Million0.0% of portfolio
-
Temasek Holdings (Private) LTD Singapore, U01.81MShares$204 Million0.88% of portfolio
About BioNTech SE
- Ticker BNTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 242,684,992
- Market Cap $27.5B
- Description
- BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II...